New drug nods for J&J, Lilly/BI, and Shire

Between FDA and European regulators, we've had three new drug approvals in 24 hours. That should give drug-launch aficionados plenty to contemplate over the weekend, even if they're trapped inside by hurricane-induced weather. Here's the list.

  • The European Commission gave the nod to Trajenta, the Boehringer Ingelheim and Eli Lilly diabetes remedy set to compete with other drugs in the DPP-4 inhibitor class: namely Merck's ($MRK) Januvia, AstraZeneca ($AZN) and Bristol-Myers Squibb's ($BMY) Onglyza and Novartis' ($NVS) Galvus. The drug is the first to come out of a diabetes partnership between Lilly and BI, launched with a $423.3 million upfront payment in January. BI-Lilly release | Report

  • Shire got the FDA nod for its Firazyr drug for hereditary angioedema, a rare genetic disease. And the company can sell it as a self-injected product to boot. This aspect is convenient, considering it's intended for acute attacks--and its competitors have to be administered by a doctor or by IV. Analysts said they're looking for $171 million in sales by 2016, up to $199 million by 2017. "They will get market share," Matrix analyst Navid Malik told Bloomberg. "This will give them really good, strong differentiation." FDA release | News | Report

  • Johnson & Johnson's ($JNJ) Janssen Pharmaceuticals won FDA approval for its oral pain drug Nucynta ER. It's an extended-release version of the company's opioid drug Nucynta. Because it's an opioid, it's no surprise the approval came with a risk evaluation and mitigation strategy (REMS). Janssen release | Report

Suggested Articles

Six pharmaceutical execs are set to head to Washington next week for pricing hearings at the House Committee on Oversight and Reform. 

After sifting through the data, one analyst figures the latest Opdivo-Keytruda showdown in kidney cancer might come down to commercial execution.

Biogen is giving former chief finance officer Jeff Capello a multimillion-dollar cash payment plus other severance benefits.